Use of antidementia drugs in German patients with Alzheimer's disease

verfasst von

Philipp Hessmann, Richard Dodel, Erika Baum, Matthias J. Müller, Greta Paschke, Bernhard Kis, Jan Zeidler, Mike Klora, Jens Peter Reese, Monika Balzer-Geldsetzer

Abstract

The objective of this study was to evaluate the use of antidementia drugs (ADDs) in patients with Alzheimer's disease (AD) regarding German guideline recommendations and to assess correlations between the use of ADDs and the patients' characteristics. A total of 395 community-dwelling and institutionalized patients with AD across all severity stages of dementia were recruited in this cross-sectional study. Associations between the prescription of ADDs and patients' sociodemographic and clinical parameters (neuropsychiatric symptoms, cognitive capacity, daily activities, and health-related quality of life) were analyzed in multiple logistic regression analyses. ADDs were prescribed in 46.6% of all participants and less often in institutionalized patients (38.2 vs. 50.4%, P=0.025). Patients with mild-to-moderate dementia had a higher chance of receiving ADDs [odds ratio (OR)=3.752, 95% confidence interval (CI): 1.166-12.080 and OR=3.526, 95% CI: 1.431-8.688] as well as those treated by neurologists/psychiatrists (OR=2.467, 95% CI: 1.288-4.726). Overall, 39% of the patients with mild cognitive deficits (Mini-Mental Status Examination 27-30) received ADDs and 21% of the mildly demented patients (Mini-Mental Status Examination 20-26) received memantine. The treatment with ADDs was in part not in line with German guideline recommendations. Particularly, the lower use of ADDs in patients not attending neuropsychiatric specialists should be further evaluated.

Organisationseinheit(en)

Center for Health Economics Research Hannover (CHERH)

Externe Organisation(en)

Georg-August-Universität Göttingen
Philipps-Universität Marburg
Universität Duisburg-Essen
Justus-Liebig-Universität Gießen
Praxis Alexander Etz
Oberberg Fachkliniken

Typ

Artikel

Journal

International Clinical Psychopharmacology

Band

33

Seiten

103-110

Anzahl der Seiten

8

ISSN

0268-1315

Publikationsdatum

03.2018

Publikationsstatus

Veröffentlicht

Peer-reviewed

Ja

ASJC Scopus Sachgebiete

Psychiatrie und psychische Gesundheit, Pharmakologie (medizinische)

Ziele für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Elektronische Version(en)

https://doi.org/10.1097/YIC.0000000000000205 (Zugang: Geschlossen)